Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using…
Read More...
Read More...